Bone Mineral Density In Patients With HIV Infection And Chronic Hepatitis C

European Meeting on HIV & Hepatitis 2020

The Prevalence Of Hepatitis B Virus Seromarkers In Patients With HIV/Hcv Coinfection. An Egyptian Cross-Sectional Study

European Meeting on HIV & Hepatitis 2020

Seroprevalence And Co-Infections HIV, HBV And HCV Among Clinic Attenders At Laquintinie Hospital In Douala, Cameroon

European Meeting on HIV & Hepatitis 2020

Using Next-Generation Sequencing To Understand The Phylogenetics And Networks Of Generalised HIV Epidemics In Africa

European Meeting on HIV & Hepatitis 2020

The Efficacy Of First-Line Therapy Based On Rpv In HIV-Infected Patients With Pre-Existing E138A Mutation In Reverse Transcriptase

European Meeting on HIV & Hepatitis 2020

Number, Type And Cost Of Microbiological Assays During HIV Pre-Exposure Prophylaxis: The Experience Of A French Hospital

European Meeting on HIV & Hepatitis 2020

Long-Acting Cabotegravir + Rilpivirine for HIV Treatment: FLAIR Week 96 Results

European Meeting on HIV & Hepatitis 2020

Optimisation of First-Line Antiretroviral Therapy (ART) for Children Living with HIV in Uganda: Translation from policy to action

European Meeting on HIV & Hepatitis 2020

Dual therapy including dolutegravir plus boosted-darunavir ensures high rate of virological control and rare resistance selection at failure in heavily treatment experienced PLWH

European Meeting on HIV & Hepatitis 2020

Dual therapy with Dolutegravir plus Lamivudine in virologically suppressed patients

European Meeting on HIV & Hepatitis 2020

Real-world effectiveness of elbasvir/grazoprevir in the treatment of patients with hepatitis C virus genotype 1a infection in Norway

European Meeting on HIV & Hepatitis 2020

HIV A1 or B Do Not Differentially Impact Cabotegravir In Vitro Potency or Durability

European Meeting on HIV & Hepatitis 2020

HIV evolution in patients initiating antiretroviral therapy during primary infection

European Meeting on HIV & Hepatitis 2020

Molecular Epidemiology of the HIV-1 Infection in Cyprus (2017-2019): A Polyphyletic Infection with an Increasing Prevalence of Drug Resistance

European Meeting on HIV & Hepatitis 2020

A changing of HIV-1 genetic diversity in Russia during the last two decades: increase of the recombinants prevalence

European Meeting on HIV & Hepatitis 2020

Phylogenetic analyses applied to the study of transmission variants in a HIV-1 positive couple

European Meeting on HIV & Hepatitis 2020

Unexpected rising in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies.

European Meeting on HIV & Hepatitis 2020

Debate: Do Integrase Inhibitors and/or TAF Lead to Weight Gain? - Dr. Jürgen Rockstroh Con Standpoint -

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Long-Acting Therapies: Which Patients Will Benefit Most? - Sharon Walmsley

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

HIV and COVID-19 co-infection: An update - Dr. Cristiana Oprea

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Abstract #7 - Development of structural changes in patients treated for VHC in the Czech Republic from viewpoint of stage of liver fibrosis, HCV genotype, age and treatment strategy - Viktor Aster, Charles University, Czech Republic

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

Managing Highly Treatment-Experienced Patients - Prof. Anca Streinu Cercel -

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

The Acute HCV Epidemic in MSM: What Have We Learned Thus Far? Christoph Boesecke

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020

ART in Women: Which Drugs are Safe and What are the Challenges? - Dr. Annette Haberl

Central and Eastern European Meeting on Viral Hepatitis and HIV 2020